These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 23282286

  • 1. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
    Lee YK, Kim SU, Kim DY, Ahn SH, Lee KH, Lee DY, Han KH, Chon CY, Park JY.
    BMC Cancer; 2013 Jan 03; 13():5. PubMed ID: 23282286
    [Abstract] [Full Text] [Related]

  • 2. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
    Lee MH, Kim SU, Kim DY, Ahn SH, Choi EH, Lee KH, Lee DY, Seong J, Han KH, Chon CY, Park JY.
    J Gastroenterol Hepatol; 2012 Feb 03; 27(2):313-22. PubMed ID: 21793906
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
    Cerban R, Ester C, Iacob S, Paslaru L, Dumitru R, Grasu M, Constantin G, Popescu I, Gheorghe L.
    Chirurgia (Bucur); 2018 Feb 03; 113(4):524-533. PubMed ID: 30183583
    [Abstract] [Full Text] [Related]

  • 4. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
    Ichikawa T, Machida N, Sasaki H, Tenmoku A, Kaneko H, Negishi R, Oi I, Fujino MA.
    Oncology; 2016 Feb 03; 91(6):317-330. PubMed ID: 27784014
    [Abstract] [Full Text] [Related]

  • 5. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
    Meguro M, Mizuguchi T, Nishidate T, Okita K, Ishii M, Ota S, Ueki T, Akizuki E, Hirata K.
    World J Gastroenterol; 2015 Apr 28; 21(16):4933-45. PubMed ID: 25945007
    [Abstract] [Full Text] [Related]

  • 6. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.
    Arai T, Kobayashi A, Ohya A, Takahashi M, Yokoyama T, Shimizu A, Motoyama H, Furusawa N, Notake T, Kitagawa N, Sakai H, Imamura H, Kadoya M, Miyagawa S.
    Int J Clin Oncol; 2014 Oct 28; 19(5):871-9. PubMed ID: 24218280
    [Abstract] [Full Text] [Related]

  • 7. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
    Lim TS, Rhee H, Kim GM, Kim SU, Kim BK, Park JY, Ahn SH, Han KH, Choi JY, Kim DY.
    J Vasc Interv Radiol; 2019 Aug 28; 30(8):1194-1200.e1. PubMed ID: 31235408
    [Abstract] [Full Text] [Related]

  • 8. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S, Rhim H, Kim YS, Kang TW, Song KD.
    Liver Int; 2016 Apr 28; 36(4):580-7. PubMed ID: 26503910
    [Abstract] [Full Text] [Related]

  • 9. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki T, Okudaira T, Toshimori A, Kawamura T, Yamago H, Nakahara H, Suga Y, Azemoto N, Miyata H, Miyamoto Y, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K.
    Oncology; 2015 Apr 28; 89(3):167-74. PubMed ID: 25999038
    [Abstract] [Full Text] [Related]

  • 10. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
    Zhao SM, Qiu LW, Zhao H, Gu WW, Yang XH, Gu ZX, Shi RF, Ni CF.
    J Cancer Res Ther; 2021 Jul 28; 17(3):707-714. PubMed ID: 34269303
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern.
    Gao F, Zhu HK, Zhu YB, Shan QN, Ling Q, Wei XY, Xie HY, Zhou L, Xu X, Zheng SS.
    Hepatobiliary Pancreat Dis Int; 2016 Aug 28; 15(4):371-7. PubMed ID: 27498576
    [Abstract] [Full Text] [Related]

  • 12. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Park WH, Shim JH, Han SB, Won HJ, Shin YM, Kim KM, Lim YS, Lee HC.
    J Vasc Interv Radiol; 2012 Jul 28; 23(7):927-36. PubMed ID: 22633621
    [Abstract] [Full Text] [Related]

  • 13. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.
    Hamamura K, Shiratori Y, Shiina S, Imamura M, Obi S, Sato S, Yoshida H, Omata M.
    Cancer; 2000 Apr 01; 88(7):1557-64. PubMed ID: 10738213
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, Takasaki K, Nakano M.
    J Gastroenterol Hepatol; 2002 Jul 01; 17(7):772-8. PubMed ID: 12121507
    [Abstract] [Full Text] [Related]

  • 15. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.
    Okamura Y, Ashida R, Ito T, Sugiura T, Mori K, Uesaka K.
    Surg Today; 2015 Dec 01; 45(12):1513-20. PubMed ID: 25527455
    [Abstract] [Full Text] [Related]

  • 16. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Lee JS, Chon YE, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kang W, Choi MS, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Kim HY, Kim TH, Yoo K, Ha Y, Kim MN, Lee JH, Hwang SG, Kim SS, Cho HJ, Cheong JY, Cho SW, Park SH, Heo NY, Hong YM, Yoon KT, Cho M, Park JG, Kang MK, Park SY, Kweon YO, Tak WY, Jang SY, Sinn DH, Kim SU, Korean TACE Study Group.
    Yonsei Med J; 2021 Jan 01; 62(1):12-20. PubMed ID: 33381930
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
    Wang Y, Chen Y, Ge N, Zhang L, Xie X, Zhang J, Chen R, Wang Y, Zhang B, Xia J, Gan Y, Ren Z, Ye S.
    Ann Surg Oncol; 2012 Oct 01; 19(11):3540-6. PubMed ID: 22532305
    [Abstract] [Full Text] [Related]

  • 18. Positive status of alpha-fetoprotein and des-gamma-carboxy prothrombin: important prognostic factor for recurrent hepatocellular carcinoma.
    Kaibori M, Matsui Y, Yanagida H, Yokoigawa N, Kwon AH, Kamiyama Y.
    World J Surg; 2004 Jul 01; 28(7):702-7. PubMed ID: 15185000
    [Abstract] [Full Text] [Related]

  • 19. Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
    Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Otsuka M, Kobara H, Kawashima H, Takayama T, Kawaguchi T, Yamasaki T, Takami T, Hepatology InVestigator Experts in Japan (HIVE-J) Study Group.
    PLoS One; 2024 Jul 01; 19(9):e0311084. PubMed ID: 39321197
    [Abstract] [Full Text] [Related]

  • 20. Alpha-fetoprotein response following transarterial chemoembolization indicates improved survival for intermediate-stage hepatocellular carcinoma.
    Liu G, Ouyang Q, Xia F, Fan G, Yu J, Zhang C, Wang D.
    HPB (Oxford); 2019 Jan 01; 21(1):107-113. PubMed ID: 30017783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.